Journal
JOURNAL OF TRANSLATIONAL MEDICINE
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12967-022-03466-9
Keywords
IL-1; Interleukin-1; Heart failure; Anakinra; Treatment; Target therapy; HFrEF
Categories
Funding
- National Heart, Lung, and Blood Institute of the National Institute of Health [R61/R33HL133943]
- National Center for Advancing Translational Sciences [UL1TR002649]
Ask authors/readers for more resources
This study aims to evaluate the effect of anakinra on cardiorespiratory fitness in patients with acute decompensated HFrEF. A randomized controlled trial will be conducted over 24 weeks to observe the impact of anakinra on oxygen consumption, echocardiographic data, and HF outcomes.
Background Heart failure (HF) is a global leading cause of mortality despite implementation of guideline directed therapy which warrants a need for novel treatment strategies. Proof-of-concept clinical trials of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, have shown promising results in patients with HF. Method We designed a single center, randomized, placebo controlled, double-blind phase II randomized clinical trial. One hundred and two adult patients hospitalized within 2 weeks of discharge due to acute decompensated HF with reduced ejection fraction (HFrEF) and systemic inflammation (high sensitivity of C-reactive protein > 2 mg/L) will be randomized in 2:1 ratio to receive anakinra or placebo for 24 weeks. The primary objective is to determine the effect of anakinra on peak oxygen consumption (VO2) measured at cardiopulmonary exercise testing (CPX) after 24 weeks of treatment, with placebo-corrected changes in peak VO2 at CPX after 24 weeks (or longest available follow up). Secondary exploratory endpoints will assess the effects of anakinra on additional CPX parameters, structural and functional echocardiographic data, noninvasive hemodynamic, quality of life questionnaires, biomarkers, and HF outcomes. Discussion The current trial will assess the effects of IL-1 blockade with anakinra for 24 weeks on cardiorespiratory fitness in patients with recent hospitalization due to acute decompensated HFrEF. Trial registration: The trial was registered prospectively with ClinicalTrials.gov on Jan 8, 2019, identifier NCT03797001.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available